Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change
- PMID: 7507184
- PMCID: PMC236502
- DOI: 10.1128/JVI.68.2.674-680.1994
Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change
Abstract
A neutralization-resistant variant of human immunodeficiency virus type 1 (HIV-1) that emerged during in vitro propagation of the virus in the presence of neutralizing serum from an infected individual has been described. A threonine-for-alanine substitution at position 582 in the gp41 transmembrane envelope glycoprotein of the variant virus was responsible for the neutralization-resistant phenotype (M.S. Reitz, Jr., C. Wilson, C. Naugle, R. C. Gallo, and M. Robert-Guroff, Cell 54:57-63, 1988). The mutant virus also exhibited reduced sensitivity to neutralization by 30% of HIV-1-positive sera that neutralized the parental virus, suggesting that a significant fraction of the neutralizing activity within these sera can be affected by the amino acid change in gp41 (C. Wilson, M. S. Reitz, Jr., K. Aldrich, P. J. Klasse, J. Blomberg, R. C. Gallo, and M. Robert-Guroff, J. Virol. 64:3240-3248, 1990). It is shown here that the change of alanine 582 to threonine specifically confers resistance to neutralizing by antibodies directed against both groups of discontinuous, conserved epitopes related to the CD4 binding site on the gp120 exterior envelope glycoprotein. Only minor differences in binding of these antibodies to wild-type and mutant envelope glycoproteins were observed. Thus, the antigenic structure of gp120 can be subtly affected by an amino acid change in gp41, with important consequences for sensitivity to neutralization.
Similar articles
-
An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.Virology. 1993 Sep;196(1):332-7. doi: 10.1006/viro.1993.1484. Virology. 1993. PMID: 8356803
-
A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.J Virol. 2000 May;74(9):4183-91. doi: 10.1128/jvi.74.9.4183-4191.2000. J Virol. 2000. PMID: 10756031 Free PMC article.
-
Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.J Virol. 1998 Sep;72(9):7099-107. doi: 10.1128/JVI.72.9.7099-7107.1998. J Virol. 1998. PMID: 9696803 Free PMC article.
-
Epitopes of HIV-1 glycoproteins recognized by the human immune system.Chem Immunol. 1993;56:91-111. Chem Immunol. 1993. PMID: 7680869 Review. No abstract available.
-
Biological consequences of human immunodeficiency virus type 1 envelope polymorphism: does variation matter? 1995 Fleming Lecture.J Gen Virol. 1996 Dec;77 ( Pt 12):2905-19. doi: 10.1099/0022-1317-77-12-2905. J Gen Virol. 1996. PMID: 9000081 Review. No abstract available.
Cited by
-
Immunotherapy with Cell-Based Biological Drugs to Cure HIV-1 Infection.Cells. 2021 Dec 28;11(1):77. doi: 10.3390/cells11010077. Cells. 2021. PMID: 35011639 Free PMC article. Review.
-
Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.PLoS Med. 2008 Jan 3;5(1):e9. doi: 10.1371/journal.pmed.0050009. PLoS Med. 2008. PMID: 18177204 Free PMC article.
-
Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation.J Virol. 2023 Sep 28;97(9):e0059223. doi: 10.1128/jvi.00592-23. Epub 2023 Sep 11. J Virol. 2023. PMID: 37696048 Free PMC article.
-
Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus.J Virol. 2016 Apr 29;90(10):4966-4980. doi: 10.1128/JVI.02851-15. Print 2016 May 15. J Virol. 2016. PMID: 26937037 Free PMC article.
-
Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.J Virol. 2004 Apr;78(7):3742-52. doi: 10.1128/jvi.78.7.3742-3752.2004. J Virol. 2004. PMID: 15016894 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials